Effect of Dexamethasone Combination with Gentamicin in Chemical Labyrinthectomy on Hearing Preservation and Vertigo Control in Patients with Unilateral Meniere's Disease: A Randomized Controlled Clinical Trial

Chemical labyrinthectomy using gentamicin is a popular method for treating intractable vertigo attacks in Meniere's disease. However, the risk of hearing loss remains a major concern for clinicians. We investigated the effect of simultaneous dexamethasone and gentamicin application on hearing preservation and vertigo control in patients with intractable unilateral Meniere's disease. A single-institutional, prospective, single-blinded, randomized clinical trial was conducted. Gentamicin-soaked Gelfoam was directly applied on the oval window following middle ear exploration. On the round window, dexamethasone-soaked Gelfoam was applied in the gentamicin with dexamethasone group (GD group, = 18), and saline-soaked Gelfoam was applied in the gentamicin with sham reagent group (GO group, = 19). The hearing change 8 weeks after the procedure and vertigo control 2-12 months after the procedure were investigated. The high-frequency hearing threshold was significantly increased in the GO group ( = 0.005 and 0.012 for 4 and 8 kHz, respectively), but not in the GD group. The short-term (2-6 months) vertigo control was more successful in the GD group (57.89% vs. 94.44%, = 0.019), but long-term control (6-12 months) was insignificant. In conclusion, the combined application of gentamicin and dexamethasone in chemical labyrinthectomy is an effective method for protecting high-frequency hearing and vertigo control.